M&A Deal Summary |
|
|---|---|
| Date | 2025-06-30 |
| Target | Capstan |
| Sector | Life Science |
| Buyer(s) | AbbVie |
| Sellers(s) | Polaris Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 2.1B USD |
| Advisor(s) | Centerview Partners (Financial) Cooley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 55,000 |
| Revenue | 56.3B USD (2024) |
AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 15 |
| Sector: Life Science M&A | 14 of 15 |
| Type: Add-on Acquisition M&A Deals | 13 of 13 |
| State: California M&A | 3 of 3 |
| Country: United States M&A | 12 of 13 |
| Year: 2025 M&A | 1 of 2 |
| Size (of disclosed) | 6 of 12 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-13 |
Nimble Therapeutics
Madison, Wisconsin, United States Nimble Therapeutics is a provider of massively parallel chemical synthesis to drug discovery. Nimble’s proprietary technology enables the synthesis and screening of millions of peptides, including scaffolded natural and modified macrocyclic peptidomimetics. Nimble Therapeutics was founded in 2019 and is based in Madison, Wisconsin. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-08-25 |
Gilgamesh - Bretisilocin
New York, New York, United States Gilgamesh's Bretisilocin is a 5-HT2A receptor agonist and 5-HT releaser, a novel, next-generation psychedelic compound designed to address development challenges observed within this class of compounds. |
Buy | $1.2B |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 5.0B USD |
| Size | Large |
| Type | Sector Agnostic |
Polaris Partners is primarily a seed, first round, and early stage venture capital investor in information technology and life science businesses. However, Polaris also focuses on private equity investments in established companies. In this area, Polaris targets high growth middle market companies in industries including technology, healthcare, digital media, consumer products and services, and business services. The firm's investments include minority growth equity investments, recapitalizations with liquidity, and leveraged buyouts. Polaris Partners was formed in 1996 and has offices in Seattle, Washington and Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 35 of 37 |
| Sector: Life Science M&A | 8 of 8 |
| Type: Add-on Acquisition M&A Deals | 17 of 19 |
| State: California M&A | 6 of 6 |
| Country: United States M&A | 32 of 34 |
| Year: 2025 M&A | 2 of 4 |
| Size (of disclosed) | 1 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-01-29 |
Quartet
New York City, New York, United States Quartet provides software solutions, behavioral health and patients a new value-based care delivery model. Quartet was founded in 2014 and is based in New York City, New York. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-09-03 |
Thirty Madison
New York, New York, United States Thirty Madison makes specialized care and clinically-proven treatments accessible and affordable for everyone by bringing the specialist experience directly into people's homes with online doctor consultations, treatment delivery, and ongoing support. The company prioritizes and enables the cultivation of meaningful doctor-patient relationships to provide the best care for successful management of lifelong conditions. Thirty Madison was formed in 2017 and is based in New York, New York. |
Sell | - |
